A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes

NCT05872620 · Completed

Last updated 2026-05-28

This clinical trial tests the medication orforglipron in adults who have obesity or are overweight and also have type 2 diabetes to see how it affects their body weight.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 1,613 people

Who can join Ages 18+ · all sexes

Timeline Started 2023-06 · est. completion 2025-08

Where 136 sites · Argentina, Australia, Brazil, China, Czechia, Germany, Greece, India, Puerto Rico, South Korea, United States

What this study is testing ClinicalTrials.gov NCT05872620 ↗

Description as written by the study sponsor.

This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22 visits.

Treatments tested

Orforglipron also known as LY3502970 Drug

Administered orally
Placebo Drug

Administered orally

Main thing measured	Mean Percent Change from Baseline in Body Weight
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Overweight, Type 2 Diabetes
GLP-1 drugs	orforglipron

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05872620 ↗